Exagen Inc
XGN
Company Profile
Business description
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Contact
1261 Liberty Way
VistaCA92081
USAT: +1 760 560-1501
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
209
Stocks News & Analysis
stocks
PayPal earnings: Growth slows, new CEO appointed
We expect to lower our fair value estimate of PayPal stock.
stocks
Morningstar initiates on ASX income play
This REIT may be an option for investors seeking income.
stocks
What Goodman’s upcoming earnings could reveal about data centre & AI growth
Answering key questions about Goodman & its data centre pipeline ahead of earnings
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,134.20 | 13.90 | -0.15% |
| CAC 40 | 8,179.50 | 1.67 | -0.02% |
| DAX 40 | 24,780.79 | 16.73 | -0.07% |
| Dow JONES (US) | 49,197.49 | 210.17 | -0.43% |
| FTSE 100 | 10,314.59 | 26.97 | -0.26% |
| HKSE | 26,834.77 | 59.20 | 0.22% |
| NASDAQ | 23,255.19 | 336.92 | -1.43% |
| Nikkei 225 | 54,720.66 | 2,065.48 | 3.92% |
| NZX 50 Index | 13,351.93 | 60.51 | -0.45% |
| S&P 500 | 6,904.93 | 71.51 | -1.03% |
| S&P/ASX 200 | 8,843.70 | 8.60 | -0.10% |
| SSE Composite Index | 4,067.74 | 51.99 | 1.29% |